Early access of bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis
IrinaÂ Vasilyeva,Â AndreiÂ Mariandyshev,Â BorisÂ Kazennyy,Â EditaÂ DavidaviÄienÄ—,Â NacerÂ Lounis,Â SofiaÂ KeimÂ on behalf of the TMC207TBC3001 study group
European Respiratory JournalÂ 2019;Â DOI:Â 10.1183/13993003.02208-2018
Globally in 2016, 19% of previously treated tuberculosis (TB) cases and 4.1% of newly diagnosed cases were reported to be resistant to isoniazid and rifampicin (MDR-TB) or rifampicin alone (RR-TB) . In 2017, 8.5% of MDR-TB cases were caused by extensively drug-resistant-TB (XDR-TB) , defined as MDR-TB with additional resistance to a fluoroquinolone (FQ) and a second-line injectable drug (SLI, amikacin, kanamycin or capreomycin). TB drug resistance, especially XDR-TB, is associated with poorer treatment outcomes [1â€“3].
This manuscript has recently been accepted for publication in theÂ European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of theÂ ERJÂ online. Please open or download the PDF to view this article.
Conflict of interest: Andrei Mariandyshev
Conflict of interest: Dr. Kazennyy has nothing to disclose.
Conflict of interest: Dr. Lounis has nothing to disclose.
Conflict of interest: Dr. Keim reports personal fees from Janssen Pharmaceutical Companies of Johnson & Johnson, outside the submitted work.
Conflict of interest: Dr. Davidaviciene has nothing to disclose.
Conflict of interest: Dr. Vasilyeva has nothing to disclose.
- Copyright Â©ERS 2019
PRAKTEK Alamat baru: